Welcome to AiCuris: The Powerhouse for Anti-Infectives

AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.   Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.


AiCuris-Team receives German Future Prize  /  AiCuris-Team mit dem Deutschen Zukunftspreis ausgezeichnet



Cooperation with Cyclenium


AiCuris to cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives

AiCuris and Cyclenium announced today the signing of a collaboration agreement focused on finding new pharmaceutical compounds for the treatment and prevention of bacterial and viral diseases.






Read more ...

AIC649 Positive Phase 1 Hepatitis B


AiCuris Reports Positive Phase 1 Clinical Trial Results with Immunomodulator AIC649 in Patients with Chronic Hepatitis B

  • Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups
  • The trial provides evidence that AIC649 stimulates the immune system of chronic hepatitis B patients
  • Further trials to study the potential of AIC649 to induce a functional cure in chronic hepatitis B virus (HBV)-infection is warranted 

 Read more ...

Job Opportunities

Join AiCuris and its quest for novel Anti-Infectives

We offer an exciting and challenging working enviroment in an innovative company with a world-class  R&D Portfolio. 






Read more ...